Copyright © 2002 by the European Society of Cardiology.
The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis
a Centre for Cardiovascular Genetics, Department of Medicine, UCLMS, The Rayne Institute, London, U.K.
b INSERMU508, Institut Pasteur de Lille, Lille, France
c University and CHRU de Lille, Lille, France
revised July 11, 2001; accepted July 18, 2001
Abstract
Aims Intracoronary ultrasound studies in humans show that chronic remodelling rather than neointimal hyperplasia is the mechanism of restenosis. Stent implantation limits this remodelling process and significantly reduces restenosis. MMP3 (Stromelysin-1), a member of the matrix metalloproteinase family may play a role in this remodelling. We used a functional polymorphism (with alleles designated 5A or 6A) in the promoter of the MMP3 gene to examine the possible role of MMP3 in restenosis.
Methods and Results Genotypes were determined in a series of consecutive patients who underwent conventional balloon coronary angioplasty without stenting (n=287) or who also had successful implantation of a Palmaz–Schatz stent (stent) (n=198). For all patients restenosis was estimated at 6 months using quantitative computer-assisted angiography. The minimal luminal diameters before and after the procedures did not differ significantly between genotypes. At follow-up in the patients without stent, those with the 6A6A genotype had an increased degree of restenosis after coronary angioplasty compared to those with one or more 5A alleles, with a greater diameter stenosis (52±21% vs 45±19%, P=0·012), and a greater late loss (0·58±0·59mm vs 0·38±0·59mm, P=0·038). By contrast, in the stented patients MMP3 genotype was not associated with any angiographically determined measure of vessel dimensions.
Conclusions These data imply the involvement of MMP3 in chronic remodelling after conventional balloon angioplasty, and suggest that the 6A6A MMP3 genotype is a genetic susceptibility factor for restenosis after angioplasty without stenting.
Key Words: Stromelysin (MMP-3), restenosis, stent, genetic polymorphism, vascular remodelling
f1 Correspondence: Professor Steve Humphries, Centre for Cardiovascular Genetics, Department of Medicine, UCLMS, The Rayne Institute, 5 University Street, London WC1E 6JJ, U.K.
References
- McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med. 1988;318:1734–1737[ISI][Medline]
- Serruys PW, de Jaegere P, Kiemeneij F. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–495
[Abstract/Free Full Text] - Bauters C, Amouyel, Bertrand ME. ACE gene polymorphism and coronary restenosis. Semin Interv Cardiol. 1999;4:145–149[Medline]
- Mintz GS, Popma JJ, Pichard AD. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35–43
[Abstract/Free Full Text] - Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinase in the pathogenesis of arteriosclerosis. Bas Res Cardiol. 1994;89:59–70
- Henney AM, Wakeley P, Davies MJ. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA. 1991;88:8154–8158
[Abstract/Free Full Text] - Galis JS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503[ISI][Medline]
- Murphy G, Reynolds JJ. Extracellular matrix degradation. Royce PM, Steinman B. Connective Tissue and Its Heritable Disorders. New York: Wiley-Liss, Inc; 1993. p. 287
- Quinones S, Buttice G, Kurkinen M. Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. Biochem J. 1994;302:471–477
- Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–215
[Abstract/Free Full Text] - Ye S, Eriksson P, Hamsten A, Kirkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13055–60
[Abstract/Free Full Text] - Humphries SE, Luong L-A, Talmud PJ. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Atherosclerosis. 1998;139:49–56[CrossRef][ISI][Medline]
- de Maat MPM, Jukema W, Ye S. Efficacy of pravastatin treatment in coronary atherosclerosis is modulated by natural variation in the stromelysin-1 promoter. Am J Cardiol. 1999;83:852–856[CrossRef][ISI][Medline]
- Hamon M, Bauters C, Amant C. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation. 1995;92:296–299
[Abstract/Free Full Text] - Amant C, Bauters C, Bodart JC. The D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation. 1997;96:56–60
[Abstract/Free Full Text] - Gurlek A, Gulec S, Karabulut H. Relation between the insertion/deletion polymorphism of the angiotensin I converting enzyme gene and restenosis after coronary stenting. J Cardiovasc Risk. 2000;7:403–407[ISI][Medline]
- Koch W, Kastrati A, Mehilli J, Bottiger C, von Beckerath N, Schomig A. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation. 2000;102:197–202
[Abstract/Free Full Text] - Terashima M, Akita H, Kanazawa K. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation. 1999;99:2717–2719
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Dumont, M. Zureik, C. Bauters, M.-C. Grupposo, D. Cottel, M. Montaye, M. Hamon, P. Ducimetiere, P. Amouyel, and T. Brousseau Association of OAZ1 Gene Polymorphisms With Subclinical and Clinical Vascular Events Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2120 - 2126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Singer, H. Holdaas, A. G. Jardine, B. Fellstrom, I. Os, G. Bermann, J. M. Meyer, and on behalf of the Assessment of Lescol in Renal Tra Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients J. Lipid Res., September 1, 2007; 48(9): 2072 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Abilleira, S. Bevan, and H. S Markus The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis J. Med. Genet., December 1, 2006; 43(12): 897 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Glueck, M. Haque, M. Winarska, S. Dharashivkar, R. N. Fontaine, B. Zhu, and P. Wang Stromelysin-1 5A/6A and eNOS T-786C Polymorphisms, MTHFR C677T and A1298C Mutations, and Cigarette-Cannabis Smoking: A Pilot, Hypothesis-Generating Study of Gene-Environment Pathophysiological Associations With Buerger's Disease. Clinical and Applied Thrombosis/Hemostasis, October 1, 2006; 12(4): 427 - 439. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Ye Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome Cardiovasc Res, February 15, 2006; 69(3): 636 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shan, W. Ying, Z. Jian-Hui, G. Wei, W. Na, and L. Yan The function of the SNP in the MMP1 and MMP3 promoter in susceptibility to endometriosis in China Mol. Hum. Reprod., June 1, 2005; 11(6): 423 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Murase, Y. Yamada, A. Hirashiki, S. Ichihara, H. Kanda, M. Watarai, F. Takatsu, T. Murohara, and M. Yokota Genetic risk and gene-environment interaction in coronary artery spasm in Japanese men and women Eur. Heart J., June 1, 2004; 25(11): 970 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Park, H.-S. Kim, H.-M. Yang, K.-W. Park, S.-W. Youn, S.-I. Jeon, D.-H. Kim, B.-K. Koo, I.-H. Chae, D.-J. Choi, et al. Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia After Balloon Injury in Rat Carotid Artery Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 885 - 891. [Abstract] [Full Text]
|
|
|
|
|
|
P. Hoppmann, W. Koch, A. Schomig, and A. Kastrati The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions Eur. Heart J., February 2, 2004; 25(4): 335 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.H. Gomma, M.A. Elrayess, C.J. Knight, E. Hawe, K.M. Fox, and S.E. Humphries The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis Eur. Heart J., December 2, 2002; 23(24): 1955 - 1962. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Lamblin, C. Bauters, X. Hermant, J.-M. Lablanche, N. Helbecque, and P. Amouyel Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease J. Am. Coll. Cardiol., July 3, 2002; 40(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||